Lead Product(s): Peptide-siRNA Conjugates
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Peptide
Partner/Sponsor/Collaborator: Alnylam Pharmaceuticals
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 27, 2021
PeptiDream will select, optimize, and synthesize peptides for each receptor. Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.